Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Delagrange
Paris, France
- Ownership
- Private
- Development stage
- Other
01
Overview
Laboratoires Delagrange was a prominent French pharmaceutical company specializing in the development of small molecule therapeutics for gastroenterology and neuropsychiatry. The company is most notably recognized for the discovery and commercialization of metoclopramide (Primpéran), a widely used antiemetic and prokinetic agent. Additionally, Delagrange developed significant antipsychotic and substituted benzamide medications such as sulpiride and tiapride. In 1991, the company was acquired by Synthélabo, which subsequently merged to become part of the global pharmaceutical leader Sanofi. The legacy of Delagrange continues through its portfolio of essential medicines that remain in use worldwide.
- Therapeutic areas
- PsychiatryGastroenterology
- Modalities
- Small molecule
- Industry
- Pharma
Beyond the preview
Go deeper on Delagrange.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Delagrange.